Intraoperative margin assessment during BCS using Perimeter B-Series OCT with ImgAssist AI 2.0 enabled surgeons to more effectively address residual cancer at the surgical margin as compared to current standard methods Primary endpoint met with statistically significant reduction in...Read more
PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25 Overall, 26% ORR across all six...Read more
LOS ANGELES / Nov 20, 2024 / Business Wire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the...Read more
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...Read more
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR)...Read more
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 RICHMOND, Calif. / Nov 19, 2024 / Business Wire / Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 23.68 3.25 | $753.41 |
| UnitedHealth | 23.50 4.07 | $600.50 |
| argenx | 17.28 3.01 | $591.82 |
| Humana | 16.19 5.83 | $293.97 |
| Alnylam Pharmaceuticals | 14.52 6.20 | $248.79 |
| Waters | 13.06 3.79 | $357.77 |
| Semler Scientific | 12.69 27.38 | $59.03 |
| Molina Healthcare | 12.14 4.30 | $294.64 |
| Medpace | 11.13 3.53 | $326.09 |
| Repligen | 10.41 8.10 | $138.90 |
| Finch Therapeutics | 9.65 536.11 | $11.45 |
| Inspire Medical Systems | 8.72 4.95 | $184.77 |
| Amgen | 8.13 2.90 | $288.08 |
| ICON | 8.07 4.13 | $203.67 |
| West Pharmaceutical | 7.56 2.49 | $311.66 |
| Forte Biosciences | 7.50 126.48 | $13.43 |
| Lantheus | 7.02 8.84 | $86.45 |
| BeiGene | 6.24 3.32 | $194.01 |
| Company | Volume | Last Trade |
|---|---|---|
| Tonix Pharmaceuticals | 654,513,644 | $0.19 |
| Quantum-Si | 278,845,174 | $1.38 |
| Pfizer | 44,158,947 | $24.92 |
| Vyome | 36,361,564 | $0.22 |
| Forte Biosciences | 29,378,859 | $13.43 |
| Eyenovia | 27,950,523 | $0.09 |
| Lineage Cell Therapeutics | 27,898,971 | $0.64 |
| Walgreens Boots Alliance | 24,873,335 | $8.21 |
| Exicure | 22,755,368 | $11.04 |
| Senseonics | 20,535,852 | $0.32 |
| Syros Pharmaceuticals | 16,804,532 | $0.28 |
| The Oncology Institute | 14,714,212 | $0.13 |
| Recursion | 14,375,750 | $6.04 |
| Aptevo Therapeutics | 12,599,179 | $0.29 |
| Seres Therapeutics | 12,189,542 | $0.83 |
| CVS Health | 11,060,119 | $56.83 |
| Bristol-Myers Squibb | 10,049,951 | $57.88 |
| Apollomics | 9,889,155 | $0.14 |
| Geron | 9,404,214 | $3.99 |
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
